ONCOLYTICS BIOTECH INC

Oncolytics insider sales reveal portfolio rebalancing amid a bullish biotech market—insiders cashing in on gains while the company gears up for Pelareorep’s commercial launch, offering a nuanced view for investors.

Insightful insider‑sale analysis shows ONCOLYTICS’ executives’ routine RSU‑driven trades aren’t a sign of distress, yet investors should watch future divestments and clinical milestones to gauge confidence in the biotech firm.

Oncolytics insider sale: Yi Qingqing liquidates 235 ADS, raising questions on confidence while insiders buy. Monitor pipeline milestones for upside.

Oncolytics Biotech insiders add to their positions, showing confidence in its reovirus therapy while navigating cash‑tight biotech waters.

Oncolytics insider trading insights: Lee Chan Henry’s 10b5‑1 buy‑sell pattern, market‑timed gains, and disciplined capital strategy explained.

Oncolytics insider buys signal confidence in REOLYSIN’s future: SVP Lee Chan Henry’s April 2026 ADS purchases highlight a long‑term bullish stance and a potential buying opportunity.

Oncolytics insider buying: SVP Lee Chan Henry’s recent ADS purchase signals executive confidence in the reovirus pipeline, hinting at a potential upside if clinical milestones are met.

Oncolytics insider buys signal renewed optimism for its reovirus platform; see how Henry’s accumulation could spark investor interest.

Oncolytics Biotech’s CEO and top execs are buying shares amid volatile price action, signaling confidence in REOLYSIN’s future and offering investors a potential hedge against short‑term swings.

Oncolytics CEO’s fresh share buys signal confidence in its reovirus cancer therapy; watch upcoming trial data and FDA milestones for potential price lift.